Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy
- Authors
- Partridge, AH[Partridge, Ann H.]; Niman, SM[Niman, Samuel M.]; Ruggeri, M[Ruggeri, Monica]; Peccatori, FA[Peccatori, Fedro A.]; Azim, HA[Jr, Hatem A. Azim]; Colleoni, M[Colleoni, Marco]; Saura, C[Saura, Cristina]; Shimizu, C[Shimizu, Chikako]; Saetersdal, AB[Saetersdal, Anna Barbro]; Kroep, JR[Kroep, Judith R.]; Mailliez, A[Mailliez, Audrey]; Warner, E[Warner, Ellen]; Borges, VF[Borges, Virginia F.]; Amant, F[Amant, Frederico]; Gombos, A[Gombos, Andrea]; Kataoka, A[Kataoka, Akemi]; Rousset-Jablonski, C[Rousset-Jablonski, Christine]; Borstnar, S[Borstnar, Simona]; Takei, J[Takei, Junko]; Lee, JE[Lee, Jeong Eon]; Walshe, JM[Walshe, Janice M.]; Borrego, MR[Borrego, Manuel Ruiz]; Moore, HC[Moore, Halle CF.]; Saunders, C[Saunders, Christobel]; Cardoso, F[Cardoso, Fatima]; Susnjar, S[Susnjar, Snezana]; Bjelic-Radisic, V[Bjelic-Radisic, Vesna]; Smith, KL[Smith, Karen L.]; Piccart, M[Piccart, Martine]; Korde, LA[Korde, Larissa A.]; Goldhirsch, A[Goldhirsch, Aron]; Gelber, RD[Gelber, Richard D.]; Pagani, O[Pagani, Olivia]
- Issue Date
- Oct-2021
- Publisher
- CHURCHILL LIVINGSTONE
- Keywords
- Breast cancer; Young women; Premenopausal women; Pregnancy desire; Endocrine therapy; Treatment interruption
- Citation
- BREAST, v.59, pp.327 - 338
- Indexed
- SCIE
SCOPUS
- Journal Title
- BREAST
- Volume
- 59
- Start Page
- 327
- End Page
- 338
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/91134
- DOI
- 10.1016/j.breast.2021.07.021
- ISSN
- 0960-9776
- Abstract
- Background: Premenopausal women with early hormone-receptor positive (HR+) breast cancer receive 5-10 years of adjuvant endocrine therapy (ET) during which pregnancy is contraindicated and fertility may wane. The POSITIVE study investigates the impact of temporary ET interruption to allow pregnancy. Methods: POSITIVE enrolled women with stage I-III HR + early breast cancer, <42 years, who had received 18-30 months of adjuvant ET and wished to interrupt ET for pregnancy. Treatment interruption for up to 2 years was permitted to allow pregnancy, delivery and breastfeeding, followed by ET resumption to complete the planned duration. Findings: From 12/2014 to 12/2019, 518 women were enrolled at 116 institutions/20 countries/4 continents. At enrolment, the median age was 37 years and 74.9 % were nulliparous. Fertility preservation was used by 51.5 % of women. 93.2 % of patients had stage I/II disease, 66.0 % were node-negative, 54.7 % had breast conserving surgery, 61.9 % had received neo/adjuvant chemotherapy. Tamoxifen alone was the most prescribed ET (41.8 %), followed by tamoxifen + ovarian function suppression (OFS) (35.4 %). A greater proportion of North American women were <35 years at enrolment (42.7 %), had mastectomy (59.0 %) and received tamoxifen alone (59.8 %). More Asian women were nulliparous (81.0 %), had node negative disease (76.2%) and received tamoxifen + OFS (56.0 %). More European women had received chemotherapy (69.3 %). Interpretation: The characteristics of participants in the POSITIVE study provide insights to which patients and doctors considered it acceptable to interrupt ET to pursue pregnancy. Similarities and variations from a regional, sociodemographic, disease and treatment standpoint suggest specific sociocultural attitudes across the world. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.